Table 4.
Adenocarcinoma | ||||||
---|---|---|---|---|---|---|
Train–Test Split | ||||||
Kidney | Ovary | Uterus | Colon | Lung | Prostate | Breast |
19 | 0 | 0 | 0 | 0 | 1 | 0 |
1 | 9 | 9 | 0 | 0 | 0 | 1 |
0 | 4 | 14 | 0 | 0 | 0 | 2 |
0 | 0 | 0 | 20 | 0 | 0 | 0 |
0 | 0 | 0 | 0 | 20 | 0 | 0 |
0 | 0 | 1 | 0 | 0 | 19 | 0 |
0 | 1 | 1 | 0 | 2 | 0 | 17 |
CM Accuracy = 84% |
Independent Test Set | ||||||
---|---|---|---|---|---|---|
Kidney | Ovary | Uterus | Colon | Lung | Prostate | Breast |
8 | 0 | 2 | 0 | 0 | 0 | 0 |
0 | 10 | 0 | 0 | 0 | 0 | 0 |
3 | 0 | 6 | 1 | 0 | 0 | 0 |
0 | 0 | 1 | 8 | 1 | 0 | 0 |
0 | 0 | 0 | 0 | 10 | 0 | 0 |
0 | 0 | 0 | 1 | 0 | 9 | 0 |
0 | 0 | 0 | 0 | 0 | 0 | 10 |
CM Accuracy = 87% |
Squamous | |||||
---|---|---|---|---|---|
Train–Test Split | |||||
Tongue-larynx | Vulva | Cervix | Penis | Lung | Anal-rectum |
24 | 0 | 1 | 0 | 0 | 0 |
0 | 3 | 0 | 0 | 0 | 0 |
2 | 0 | 6 | 0 | 1 | 0 |
4 | 1 | 0 | 0 | 0 | 0 |
1 | 0 | 1 | 0 | 16 | 0 |
0 | 0 | 0 | 0 | 0 | 8 |
CM Accuracy = 83% |
Independent Test Set | |||||
---|---|---|---|---|---|
Tongue-larynx | Vulva | Cervix | Penis | Lung | Anal-rectum |
11 | 0 | 0 | 0 | 0 | 0 |
2 | 0 | 0 | 0 | 0 | 0 |
0 | 0 | 6 | 0 | 0 | 0 |
0 | 0 | 0 | 1 | 1 | 0 |
0 | 0 | 0 | 0 | 4 | 0 |
0 | 0 | 0 | 0 | 0 | 4 |
CM Accuracy = 90% |
Neuroendocrine | ||
---|---|---|
Train–Test Split | ||
Small-bowel | Pancreas | Lung |
9 | 0 | 2 |
0 | 7 | 0 |
0 | 0 | 11 |
CM Accuracy = 93% |
Independent Test Set | ||
---|---|---|
Small-bowel | Pancreas | Lung |
4 | 0 | 1 |
0 | 4 | 0 |
0 | 0 | 11 |
CM Accuracy = 87% |
Samples from the Moffitt and expO data sets were first grouped and tumors randomly selected for both training and independent validation.